How to Appeal an Insurance Denial for GLP-1 Medications (Step-by-Step)

Disclaimer: Insurance and cost information changes frequently. Always verify current coverage details with your insurer and prescriber.

Why GLP-1 Claims Are Denied

Understanding why your claim was denied is the essential first step, because the strategy for your appeal depends entirely on the reason given. GLP-1 medication denials fall into several common categories, each requiring a different response.

No prior authorization obtained. This is the most common and often the most straightforward denial to address. Many plans require prior authorization (PA) for GLP-1 medications, and if your prescriber submitted the prescription without completing the PA process first, an automatic denial results. The fix is to submit the prior authorization with complete clinical documentation — this is not technically an appeal but a completion of the initial process.

Coverage exclusion for weight loss or obesity drugs. Some plans explicitly exclude anti-obesity medications from their formulary. This type of denial is harder to overturn through a clinical appeal alone, because it reflects a plan design choice rather than a clinical judgment. However, if the drug was prescribed for a covered diagnosis — such as Type 2 diabetes, cardiovascular disease risk reduction, or sleep apnea — the exclusion may not apply, and an appeal based on diagnosis coding can be effective.

Step therapy requirements not met. Many plans require patients to try and fail one or more other medications before GLP-1s are approved. If your prior authorization did not document prior trials of first-line agents (typically metformin for diabetes, or diet and exercise for obesity), the PA may have been denied for failure to meet step therapy criteria. Your appeal should document all prior treatments and their outcomes.

BMI or comorbidity criteria not met. Most plans with GLP-1 coverage for obesity require a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related comorbidity (hypertension, Type 2 diabetes, dyslipidemia, sleep apnea). If your physician did not document these in the PA, the denial may cite unmet criteria even if you clearly qualify clinically.

Diagnosis coding errors. A mismatch between the ICD-10 code on the prescription and the plan's approved indications can trigger a denial. For example, a prescription submitted with a code for obesity management (E66.9) on a plan that only covers GLP-1s for diabetes (E11.x) will be denied. Your prescriber's billing office should review the diagnosis codes on all PA submissions.

Step 1: Review Your Denial Letter Carefully

Your insurer is required to send you a written Explanation of Benefits (EOB) or a denial notice that explains: the specific reason for the denial; the plan language, clinical criteria, or coverage policy on which the denial is based; and your rights to appeal, including the deadline and process for doing so.

Read this document very carefully. Insurance denials are sometimes vague — phrases like "not medically necessary" or "excluded service" — and you have the right to request more specific information. You can contact the insurer and ask for the exact clinical criteria they use to evaluate medical necessity for the drug in question, and for a copy of the coverage policy or formulary exclusion on which they relied. This information is critical for structuring your appeal.

Note the appeal deadline prominently. For internal appeals at most insurers and ERISA-governed employer plans, you typically have 180 days from the denial date to file. For urgent or ongoing care, shorter expedited timelines apply. Missing the appeal deadline means losing your appeal rights — put the deadline on your calendar immediately.

Step 2: Gather Your Medical Documentation

A successful appeal is built on documentation. Before you write a single word of your appeal letter, gather every piece of relevant medical evidence. The stronger and more specific your documentation, the better your chances.

Request the following from your physician's office:

• Recent visit notes documenting your BMI, weight history, and relevant diagnoses
• Lab results including A1C (if diabetic or pre-diabetic), lipid panel, and any relevant metabolic markers
• Documentation of all previous weight-loss treatments tried, including dates, duration, and outcomes
• Records of comorbid conditions: hypertension, sleep apnea, cardiovascular disease, dyslipidemia, osteoarthritis
• A detailed Letter of Medical Necessity written specifically for the appeal (more on this below)

Also gather relevant external evidence: clinical practice guidelines from professional societies (American Heart Association, American Diabetes Association, Obesity Medicine Association) that recommend pharmacotherapy for patients with your clinical profile are powerful supporting documents. Peer-reviewed studies demonstrating the efficacy and safety of semaglutide or tirzepatide add further weight.

For cardiovascular risk reduction, cite the SELECT trial (New England Journal of Medicine, 2023): semaglutide reduced major adverse cardiovascular events (non-fatal heart attack, non-fatal stroke, cardiovascular death) by 20% in overweight or obese patients without diabetes who had established cardiovascular disease. This is landmark data that demonstrates GLP-1 medications are not just "weight-loss drugs" but serious cardiovascular medicines — framing that directly challenges denials based on obesity exclusions.

Step 3: File Your Internal Appeal

The internal appeal is your first formal recourse after a denial. Under the ACA and ERISA, insurers must allow at least one level of internal appeal, and must respond within defined timelines: 30 days for pre-service (before you receive care) appeals, 60 days for post-service (after care) appeals, and 72 hours for urgent/expedited appeals.

Your appeal letter should be structured, clear, and clinical — not emotional. Insurance reviewers respond to medical evidence and policy arguments, not personal hardship narratives (though brief context is appropriate). Structure your letter as follows:

• Opening: State your name, member ID, claim number, date of denial, and the drug being appealed
• Summary of the denial reason and why you believe it is incorrect
• Clinical summary: your diagnoses, BMI, comorbidities, and treatment history
• Why the drug is medically necessary: specific, evidence-based arguments addressing the denial reason
• Supporting evidence: cite clinical guidelines, trial data (SELECT, SURMOUNT-1, STEP trials), and your physician's letter
• Closing: request for full approval with a specific response deadline

Submit your appeal by certified mail or via the insurer's secure member portal, keeping copies of everything. If submitting by mail, request a return receipt. The paper trail matters if you need to escalate to external review.

Step 4: External Appeals and State Resources

If your internal appeal is denied, you have the right to an independent external review. Under the ACA, all non-grandfathered health plans must allow external appeals of denials involving medical judgment (including medical necessity determinations). ERISA plans also provide external appeal rights for clinical matters.

External appeals are conducted by Independent Review Organizations (IROs) — third-party entities staffed by medical professionals with no financial relationship with your insurer. The IRO reviews your medical documentation, the insurer's rationale, and applicable clinical standards, then issues a binding decision. If the IRO rules in your favor, your insurer must cover the drug.

External appeal reversal rates for well-documented GLP-1 cases are meaningful — industry data suggests 30–50% of external appeals result in the original denial being overturned. The process is free for you (the insurer pays the IRO fee), and you typically have four months from the final internal denial to request external review.

Your state insurance commissioner is another resource. Most states have a consumer assistance program or insurance ombudsman that can advise you on the appeals process, help you file a complaint against an insurer that is not following the rules, and sometimes facilitate resolution. Complaints to the state insurance commissioner can also create additional pressure on insurers to revisit denials.

The Peer-to-Peer Review Option

The peer-to-peer review — also called a physician-to-physician review or P2P — is often the most effective single intervention in the appeals process. It involves your prescribing physician calling the insurance company's medical director (or their reviewing physician) directly to discuss your case.

Peer-to-peer reviews are typically available at the prior authorization stage (after an initial PA denial) rather than during the formal appeals process, though some insurers offer them at the appeal level as well. Ask your physician's office explicitly: "Can you request a peer-to-peer review with the insurance medical director?" Many practices now have staff — medical assistants, care coordinators, or dedicated prior auth specialists — who manage this process routinely.

The power of the peer-to-peer is that a physician speaking directly to another physician about a specific patient's clinical situation is far more persuasive than written documentation alone. The reviewing physician can ask clarifying questions, the prescriber can explain nuances not captured in the record, and many cases that would be denied on paper are approved in this conversation.

To maximize the effectiveness of the peer-to-peer, prepare your prescriber with a clear clinical brief: your BMI and history, all comorbidities, prior treatments and their outcomes, and the specific clinical guideline or evidence base that supports the prescription. Your physician should also be prepared to reference the SELECT trial data if cardiovascular risk is a factor — this is often the most compelling argument for plans that otherwise exclude obesity drugs, because it reframes the prescription as a cardiovascular intervention.

Timeline and Tips for Success

Here is a realistic timeline for navigating the appeal process from denial to resolution:

• Days 1–5: Receive and fully review the denial letter. Contact your prescriber's office to inform them and request a peer-to-peer review immediately.
• Days 5–14: Peer-to-peer review conducted (if available). Simultaneously begin gathering documentation for the internal appeal.
• Days 14–30: Submit your written internal appeal with complete documentation, physician letter, and clinical evidence.
• Days 30–60: Insurer reviews and responds to internal appeal. (ACA mandates 30-day response for pre-service, 60 days for post-service.)
• If denied: Request external review within four months. The IRO has 45 days to issue its decision (or 72 hours for urgent cases).

Tips that meaningfully improve success rates: Always submit appeals in writing rather than only by phone — verbal communications create no paper trail. Attach the relevant published clinical guidelines (downloadable free from the Obesity Medicine Association and AHA websites) rather than just citing them. Have your physician co-sign the appeal letter or provide a separate letter — physician-authored appeals carry significantly more weight than patient-only submissions. Follow up with the insurer at the midpoint of their review window to confirm receipt and ask whether any additional information is needed. And do not give up after an internal denial — the external appeal process exists precisely because internal reviews can be biased toward denial, and IROs operate independently.

While your appeal is pending, explore whether you qualify for a manufacturer savings card or Patient Assistance Program to bridge the gap. Being without medication while an appeal is being processed can take weeks or months — having an interim supply through an assistance program means your treatment does not have to stop while you fight for coverage.